01
Cash & equivalents decreased 45.8%
Cash & equivalents changed -45.8% from the comparable as-filed period.
$31.5M→$17.1MComparable → current
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTProtara Therapeutics, Inc.'s latest supported as-filed period reports revenue of $2.9M. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -45.8% from the comparable as-filed period.
Net income changed -44.8% from the comparable as-filed period.
Operating income changed -40.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
TARA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001213900-26-087508SEC ↗8-KAug 11, 2026Period Aug 11, 20260001213900-26-087506SEC ↗4Jul 1, 2026Period Jun 29, 20260001213900-26-074238SEC ↗8-KJun 29, 2026Period Jun 26, 20260001213900-26-073184SEC ↗4Jun 16, 2026Period Jun 15, 20260001213900-26-069250SEC ↗4Jun 16, 2026Period Jun 15, 20260001213900-26-069249SEC ↗4Jun 16, 2026Period Jun 15, 20260001213900-26-069248SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jun 30, 2026Filed Jul 1, 2026 | Shefferman JesseCEO and President | GiftDirect | 14,000 | $0 | $0 | Form 4 ↗ |
| Jun 30, 2026Filed Jul 1, 2026 | Shefferman JesseCEO and President | GiftDirect | 7,000 | $0 | $0 | Form 4 ↗ |
| Jun 30, 2026Filed Jul 1, 2026 | Shefferman JesseCEO and President | GiftDirect | 4,000 | $0 | $0 | Form 4 ↗ |
| Jun 30, 2026Filed Jul 1, 2026 | Shefferman JesseCEO and President | GiftDirect | 5,000 | $0 | $0 | Form 4 ↗ |
| Jun 29, 2026Filed Jul 1, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +57.4% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Stock-based compensation changed +53.3% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001213900-26-069247| Option ExerciseDirect |
| 215,687 |
| $2 |
| $411,962 |
| Form 4 ↗ |
| Jun 29, 2026Filed Jul 1, 2026 | Shefferman JesseCEO and President | Open Market SaleDirect | 215,687 | $4 | $882,160 | Form 4 ↗ |
| Jun 29, 2026Filed Jul 1, 2026 | Shefferman JesseCEO and President | Option ExerciseDirect | 215,687 | $0 | $0 | Form 4 ↗ |